Neurocrine Biosciences Inc. reports biopharmaceutical developments across neurological, psychiatric, endocrine and immunological disorders. Recurring updates include commercial and clinical information for INGREZZA for tardive dyskinesia and chorea associated with Huntington's disease, CRENESSITY for classic congenital adrenal hyperplasia, and approved therapies for endometriosis and uterine fibroids.
Company news also covers CAHtalyst clinical data, peer-reviewed publications on glucocorticoid dosing and the Tardive Dyskinesia Impact Scale, pipeline programs such as NBIP-'2118, financial results, healthcare conference participation, and governance or capital-structure matters tied to Neurocrine's public-company reporting.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Neurocrine Biosciences (NASDAQ: NBIX) has announced a conference call and webcast scheduled for May 3, 2023, to discuss its Q1 2023 financial results. The press release will be available at 4:30 a.m. PT / 7:30 a.m. ET, followed by the conference call at 5:00 a.m. PT / 8:00 a.m. ET. Interested parties can join via phone using the domestic number 800-895-3361 or the international number 785-424-1062, with Conference ID NBIX. A webcast of the call will be accessible on the company’s website, and a replay will be available for one month afterward.
Neurocrine Biosciences (NASDAQ: NBIX) will present at the Stifel 2023 CNS Days on Tuesday, March 28, 2023, at 12:30 p.m. Eastern Time. Eiry Roberts, Chief Medical Officer, and Kyle Gano, Chief Business Development and Strategy Officer, will represent the company.
The live presentation will be webcasted and can be accessed on Neurocrine's website under the Investors section. A replay of the event will be available about one hour after the presentation and archived for one month.
Neurocrine Biosciences, Inc. (NASDAQ: NBIX) announced the publication of data from the RE-KINECT study, the largest real-world analysis of patients with possible tardive dyskinesia (TD). The study showed that patients aware of their involuntary movements reported significant negative impacts on their health and social functioning. An important finding was the disconnect between clinician-rated TD severity and patient perceptions. The study assessed 1,148 patients and highlighted the need for clinicians to evaluate both the presence of TD and its effects on daily life for better treatment plans. This research underlines the necessity for comprehensive assessments of the quality of life in TD patients.
Neurocrine Biosciences (Nasdaq: NBIX) announced the presentation of data from three in vitro studies regarding the dissolution performance of INGREZZA® (valbenazine) capsule contents when mixed with soft foods or delivered via G-tube. Results indicated that crushing the capsules did not affect dissolution performance compared to whole capsules. This is significant for elderly patients with tardive dyskinesia, who may have difficulty swallowing. The data will be presented at the AMDA-PALTC23 Annual Conference from March 9-12 in Tampa, Florida, demonstrating the drug's versatility in administration methods.
Neurocrine Biosciences (NASDAQ: NBIX) will participate in two key investor conferences in Miami this March. The first event is the Barclays Global Healthcare Conference on March 15, 2023, where CEO Kevin Gorman and CFO Matt Abernethy will present at 10:45 a.m. Eastern Time. The second event is the Jefferies Biotech on the Bay Summit on March 16, 2023. Interested parties can access a live webcast of the Barclays presentation via their website, with a replay available for one month after the event.
On March 3, 2023, Neurocrine Biosciences (NASDAQ: NBIX) presented data at the AAGP 2023 Annual Meeting in New Orleans, focusing on the long-term treatment of tardive dyskinesia (TD) in older and elderly patients using INGREZZA (valbenazine). The findings showed that over 80% of patients aged 65+ achieved a clinically meaningful reduction in TD symptoms after 48 weeks of treatment. The study highlighted significant improvements in AIMS total scores and psychiatric stability across both age groups. The results are expected to inform treatment decisions for older adults at risk of TD.